TokenPost·
Novartis Presents Two-Year Ianalumab Results in Sjögren’s Disease
Results from the NEPTUNUS extension study showed further improvements in disease activity.
More news
- TokenPostStripe Completes OpenRouter Acquisition to Expand Its AI Infrastructure Business
- TokenPostBeefy Finance Adds Support for Aave V4 Tokenized Stocks on Base
- TokenPostGemini’s 10-Token 2026 Loss Ranking Puts Bitcoin Cash Down 61.76%
- TokenPostStripe Completes OpenRouter Acquisition, Adding Platform Used by More Than 10 Million
- TokenPostNvidia Hires Wachtell Lipton to Investigate Jensen Huang Relationship
- TokenPostBank of America Sees Memory Upcycle Through 2027, Could Avoid 2028 Downturn